Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.61 |
| ▸ | LCK | P06239 | 7/20 | 0.61 |
| ▸ | KDR | P35968 | 6/20 | 0.61 |
| ▸ | TEK | Q02763 | 5/20 | 0.61 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.61 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.61 |
| ▸ | IGF1R | P08069 | 5/20 | 0.59 |
| ▸ | EGFR | P00533 | 9/20 | 0.56 |
| ▸ | ABL1 | P00519 | 8/20 | 0.56 |
| ▸ | ABL2 | P42684 | 8/20 | 0.56 |
| ▸ | LYN | P07948 | 3/20 | 0.54 |
| ▸ | RET | P07949 | 2/20 | 0.54 |
| ▸ | INSR | P06213 | 2/20 | 0.54 |
| ▸ | CSF1R | P07333 | 2/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | BLK | P51451 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | NPM1 | P06748 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885605 | 0.97 | SRC (0.58) | SRCLCKKDRTEKLIMK1 | |
| SCHEMBL2071754 | 0.95 | IGF1R (0.59) | SRCLCKKDRTEKLIMK1 | |
| SCHEMBL6461905 | 0.93 | LCK (0.59) | SRCLCKKDRTEKLIMK1 | |
| SCHEMBL6461790 | 0.93 | SRC (0.59) | SRCLCKKDRTEKLIMK1 | |
| SCHEMBL2071878 | 0.92 | SRC (0.53) | SRCLCKKDRTEKLIMK1 | |
| SCHEMBL2072511 | 0.92 | IGF1R (0.59) | SRCLCKKDRTEKLIMK1 | |
| SCHEMBL2074582 | 0.92 | IGF1R (0.60) | SRCLCKKDRTEKLIMK1 | |
| Hydrochloric Acid SCHEMBL2071991 | 0.91 | SRC (0.52) | SRCLCKKDRTEKLIMK1 | |
| SCHEMBL6883793 | 0.91 | LCK (0.76) | SRCLCKKDRTEKLIMK1 | |
| SCHEMBL2074654 | 0.90 | IGF1R (0.60) | SRCLCKKDRTEKLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1114052-B1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-1114052-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017202-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | SRC 46/4885LCK 1/4885KDR 3981/4885 |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | LCK, PPP5C, DUSP1 | SRC 89/4885LCK 1/4885KDR 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.